Literature DB >> 26105523

The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA "uptake" on the hepatobiliary phase of MR imaging.

Vincenza Granata1, Orlando Catalano2, Roberta Fusco1, Fabiana Tatangelo3, Daniela Rega4, Guglielmo Nasti5, Antonio Avallone6, Mauro Piccirillo7, Francesco Izzo7, Antonella Petrillo1.   

Abstract

PURPOSE: To describe the MRI findings in colorectal cancer liver metastases using gadoxetic acid (Gd-EOB-DTPA), with special emphasis on the target feature seen on the hepatobiliary phase.
MATERIAL AND METHODS: The medical records of 45 colorectal cancer patients with an overall number of 150 liver metastases were reviewed. All patients underwent Gd-EOB-DTPA-enhanced MRI before any kind of treatment. We retrospectively evaluated, for each lesion, the signal intensity on the T1-weighted, T2-weighted, and diffusion-weighted images. Additionally, the enhancement pattern during the arterial-, portal-, equilibrium-, and hepatobiliary-phase was assessed. Fourteen lesions had a pathological correlation.
RESULTS: Lesions size was 5-40 mm (mean 15 mm). All metastases were hypointense on T1-w imaging. Ninety-nine lesions (66%) had a central area of very high signal intensity on T2-w imaging. Fifty-one metastases (34%) were hyperintense on the T2-w images. In DWI, all lesions had a restricted diffusion. The mean ADC value was 1.31 × 10(-3) mm(2)/s (range 1.10-1.45 × 10(-3) mm(2)/s). During the arterial-phase imaging, 61 lesions (41%) showed a rim enhancement, while 89 lesions (59%) appeared as hypointense. All lesions had low signal intensity in the portal and equilibrium phase. Thirty-nine percent of the lesions also showed an enhancing rim on the portal-phase images. During the hepatobiliary phase, 80 lesions (53.3%) were hypointense, while 70 lesions (46.7%) had a target appearance.
CONCLUSION: A number of metastases show an atypical contrast medium uptake during the hepatobiliary phase of gadoxetic acid-enhanced MRI, consisting in a target appearance.

Entities:  

Keywords:  Colorectal cancer; Gadoxetic acid; Liver metastasis; Magnetic resonance imaging

Mesh:

Substances:

Year:  2015        PMID: 26105523     DOI: 10.1007/s00261-015-0488-7

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  18 in total

1.  Uncommon neoplasms of the biliary tract: radiological findings.

Authors:  Vincenza Granata; Roberta Fusco; Orlando Catalano; Salvatore Filice; Antonio Avallone; Mauro Piccirillo; Maddalena Leongito; Raffaele Palaia; Roberto Grassi; Francesco Izzo; Antonella Petrillo
Journal:  Br J Radiol       Date:  2017-07-21       Impact factor: 3.039

2.  The value of gadoxetic acid-enhanced MRI for differentiation between hepatic microabscesses and metastases in patients with periampullary cancer.

Authors:  Seo-Youn Choi; Young Kon Kim; Ji Hye Min; Dong Ik Cha; Woo Kyoung Jeong; Won Jae Lee
Journal:  Eur Radiol       Date:  2017-03-24       Impact factor: 5.315

3.  Peribiliary liver metastases MR findings.

Authors:  Vincenza Granata; Roberta Fusco; Orlando Catalano; Antonio Avallone; Maddalena Leongito; Francesco Izzo; Antonella Petrillo
Journal:  Med Oncol       Date:  2017-06-01       Impact factor: 3.064

4.  Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Sergio Venanzio Setola; Andrea Belli; Alessandro Ottaiano; Guglielmo Nasti; Michelearcangelo La Porta; Ginevra Danti; Salvatore Cappabianca; Carmen Cutolo; Antonella Petrillo; Francesco Izzo
Journal:  Radiol Med       Date:  2021-11-29       Impact factor: 3.469

5.  Gadoxetic acid disodium-enhanced MR imaging of cholangiolocellular carcinoma of the liver: imaging characteristics and histopathological correlations.

Authors:  Hiroki Haradome; Toshiyuki Unno; Hiroyuki Morisaka; Yusuke Toda; Thomas C Kwee; Hiroshi Kondo; Keiji Sano; Tomoaki Ichikawa; Fukuo Kondo; Masahiko Sugitani; Tadatoshi Takayama
Journal:  Eur Radiol       Date:  2017-04-24       Impact factor: 5.315

6.  Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.

Authors:  Vincenza Granata; Roberta Fusco; Orlando Catalano; Antonio Avallone; Raffaele Palaia; Gerardo Botti; Fabiana Tatangelo; Francesco Granata; Marco Cascella; Francesco Izzo; Antonella Petrillo
Journal:  PLoS One       Date:  2017-06-20       Impact factor: 3.240

7.  Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI) for Hepatocellular carcinoma: correlation with histologic grade.

Authors:  Vincenza Granata; Roberta Fusco; Orlando Catalano; Benedetta Guarino; Francesco Granata; Fabiana Tatangelo; Antonio Avallone; Mauro Piccirillo; Raffaele Palaia; Francesco Izzo; Antonella Petrillo
Journal:  Oncotarget       Date:  2016-11-29

8.  Evaluating segmental liver function using T1 mapping on Gd-EOB-DTPA-enhanced MRI with a 3.0 Tesla.

Authors:  Zhi-Peng Zhou; Li-Ling Long; Wei-Jia Qiu; Ge Cheng; Li-Juan Huang; Teng-Fei Yang; Zhong-Kui Huang
Journal:  BMC Med Imaging       Date:  2017-03-01       Impact factor: 1.930

9.  Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.

Authors:  Mansur A Ghani; Arash Fereydooni; Evan Chen; Brian Letzen; Fabian Laage-Gaupp; Nariman Nezami; Yanhong Deng; Geliang Gan; Vinayak Thakur; MingDe Lin; Xenophon Papademetris; Ruediger E Schernthaner; Steffen Huber; Julius Chapiro; Kelvin Hong; Christos Georgiades
Journal:  Eur Radiol       Date:  2021-06-01       Impact factor: 5.315

10.  Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.

Authors:  Vincenza Granata; Roberta Fusco; Orlando Catalano; Salvatore Filice; Daniela Maria Amato; Guglielmo Nasti; Antonio Avallone; Francesco Izzo; Antonella Petrillo
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.